Dario Altieri named CEO of The Wistar Institute

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

DARIO ALTIERI was named CEO of The Wistar Institute, following the announced retirement of President and CEO Russel Kaufman, effective March 2. Altieri will continue to serve as director of the Wistar Cancer Center, and Kaufman will become president emeritus.

Altieri also serves as Wistar’s executive vice president, chief scientific officer and the Robert and Penny Fox Distinguished Professor. He joined Wistar in 2010.

Kaufman joined Wistar in 2002 from Duke University School of Medicine where he was vice dean for Education and Academic Affairs as well as chancellor for Academic Affairs for the Duke University Health System.

Kaufman led the institute during its ongoing $35 million capital campaign, which began in 2010. The campaign supported Wistar’s first major building project since 1976, the Robert and Penny Fox Tower. According to the institute, Wistar has raised close to $80 million during Kaufman’s nearly 13 years.

YOU MAY BE INTERESTED IN

At the Sept. 4 meeting of the National Cancer Advisory Board, NCI Principal Deputy Director Douglas R. Lowy provided an overview of how NCI is weathering the maelstrom of executive orders, policy changes, and funding uncertainties that has come down on federal agencies and research institutes since Donald Trump’s inauguration in January. 
A Senate hearing that the administration hoped would be a routine check-in on the president’s 2026 MAHA-driven healthcare agenda erupted into a political firestorm as senators jumped at their first opportunity to confront HHS Secretary Robert F. Kennedy Jr. over the chaos engulfing the Centers for Disease Control and Prevention.
In December 1971, President Richard Nixon signed the National Cancer Act and declared a “War on Cancer.” In the past 54 years, the U.S. has invested $180 billion nominally, or approximately $322 billion when adjusted for inflation, in cancer research. This investment has paid dividends with more than 100 anticancer drugs brought to market in half a century—virtually all traceable to National Cancer Institute funding. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login